In a recruited AIDS patient with acute lymphoblastic leukemia, donor-derived HSPCs carrying the ablated CCR5 can differentiate into multiple hematopoietic lineages and persist for more than 19 months without gene editing-related adverse events, demonstrating the feasibility of long-term engraftment of gene-edited cells (151). The gene discussed is CCR5; the disease is acute lymphoblastic leukemia.